Compare Gartner Inc (IT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Novavax Inc — how do they compare? Gartner Inc trades at $195.41 (market cap $11.73B), while Novavax Inc trades at $11.04 (market cap $1.85B). The key difference: Gartner Inc is far larger — about 6.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Novavax Inc for 59 Days on average.
| IT | NVAX | |
|---|---|---|
Market Cap | $11.73B | $1.85B |
Volume | 736,899 | 8,362,562 |
Sector | Technology | Health |
52-Week High | $258.17 | $12.56 |
52-Week Low | $125.68 | $6.22 |
Typical Hold Time | 64 Days | 59 Days |
Enterprise Value | $13.48B | $1.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.77, up 0.46% today, showing strong technical momentum with a bullish moving average signal. The company maintains robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and impressive profitability metrics including 69.63% gross margin and 113.58% ROE. Recent news highlights Gartner's leadership position in AI advisory services and strong industry recognition.
While valuation appears reasonable with P/E of 16.71, the stock faces headwinds from negative cash flow trends and a high P/B ratio of 160.06. Analyst consensus is mixed with 27.78% buy ratings but a consensus price target below current levels at $174.63, suggesting limited near-term upside potential despite strong business fundamentals.
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
